CLEC4C and systemic lupus erythematosus: BIIB059, a monoclonal antibody (anti-CLEC4C) developed for application in SLE, rapidly internalizes pDC surface receptors by binding to CLEC4C, thereby effectively inhibiting the production of IFN-1, cytokines, and chemokines [49].